More than 95% of polycythemia vera (PV), and up to 50% of essential thrombocythemia (ET) and primary myelofibrosis (PMF) patients harbour the JAK2 V617F mutation 5–6. This evidence concerns the gene JAK2 and acquired polycythemia vera.